These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Synthesis of novel pyrrole and pyrrolo[2,3-d]pyrimidine derivatives bearing sulfonamide moiety for evaluation as anticancer and radiosensitizing agents. Ghorab MM; Ragab FA; Heiba HI; Youssef HA; El-Gazzar MG Bioorg Med Chem Lett; 2010 Nov; 20(21):6316-20. PubMed ID: 20850308 [TBL] [Abstract][Full Text] [Related]
26. Discovery of new pyrimidopyrrolizine/indolizine-based derivatives as P-glycoprotein inhibitors: Design, synthesis, cytotoxicity, and MDR reversal activities. Shawky AM; Abdalla AN; Ibrahim NA; Abourehab MAS; Gouda AM Eur J Med Chem; 2021 Jun; 218():113403. PubMed ID: 33823396 [TBL] [Abstract][Full Text] [Related]
27. Antitumor activity of novel pyrrolo[2,3-d]pyrimidin-4-ones. Atapour-Mashhad H; Tayarani-Najaran Z; Davoodnia A; Moloudi R; Mousavi SH Drug Chem Toxicol; 2011 Jul; 34(3):271-6. PubMed ID: 21649481 [TBL] [Abstract][Full Text] [Related]
28. Design and synthesis of novel 1,2,3-triazole-pyrimidine hybrids as potential anticancer agents. Ma LY; Pang LP; Wang B; Zhang M; Hu B; Xue DQ; Shao KP; Zhang BL; Liu Y; Zhang E; Liu HM Eur J Med Chem; 2014 Oct; 86():368-80. PubMed ID: 25180925 [TBL] [Abstract][Full Text] [Related]
29. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling. Adel M; Serya RAT; Lasheen DS; Abouzid KAM Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512 [TBL] [Abstract][Full Text] [Related]
30. Novel thienopyrimidine derivatives as dual EGFR and VEGFR-2 inhibitors: design, synthesis, anticancer activity and effect on cell cycle profile. Mghwary AE; Gedawy EM; Kamal AM; Abuel-Maaty SM J Enzyme Inhib Med Chem; 2019 Dec; 34(1):838-852. PubMed ID: 30919701 [TBL] [Abstract][Full Text] [Related]
31. Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents. Wang R; Chen Y; Zhao X; Yu S; Yang B; Wu T; Guo J; Hao C; Zhao D; Cheng M Eur J Med Chem; 2019 Dec; 183():111716. PubMed ID: 31550660 [TBL] [Abstract][Full Text] [Related]
32. Dual inhibitors of thymidylate synthase and dihydrofolate reductase as antitumor agents: design, synthesis, and biological evaluation of classical and nonclassical pyrrolo[2,3-d]pyrimidine antifolates(1). Gangjee A; Jain HD; Phan J; Lin X; Song X; McGuire JJ; Kisliuk RL J Med Chem; 2006 Feb; 49(3):1055-65. PubMed ID: 16451071 [TBL] [Abstract][Full Text] [Related]
33. Discovery of novel pyrrolopyrimidine/pyrazolopyrimidine derivatives bearing 1,2,3-triazole moiety as c-Met kinase inhibitors. Wang L; Liu X; Duan Y; Li X; Zhao B; Wang C; Xiao Z; Zheng P; Tang Q; Zhu W Chem Biol Drug Des; 2018 Jul; 92(1):1301-1314. PubMed ID: 29575727 [TBL] [Abstract][Full Text] [Related]
34. Synthesis and biological evaluation of 2,6-disubstituted-9H-purine, 2,4-disubstitued-thieno[3,2-d]pyrimidine and -7H-pyrrolo[2,3-d]pyrimidine analogues as novel CHK1 inhibitors. Tian C; Han Z; Li Y; Wang M; Yang J; Wang X; Zhang Z; Liu J Eur J Med Chem; 2018 May; 151():836-848. PubMed ID: 29684894 [TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of classical and nonclassical 6-arylthio-2,4-diamino-5-ethylpyrrolo[2,3-d]pyrimidines as antifolates. Gangjee A; Zeng Y; Talreja T; McGuire JJ; Kisliuk RL; Queener SF J Med Chem; 2007 Jun; 50(13):3046-53. PubMed ID: 17552508 [TBL] [Abstract][Full Text] [Related]
36. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidine derivatives containing 1,8-naphthyridine-4-one fragment. Zhang J; Chen P; Duan Y; Xiong H; Li H; Zeng Y; Liang G; Tang Q; Wu D Eur J Med Chem; 2021 Apr; 215():113273. PubMed ID: 33601310 [TBL] [Abstract][Full Text] [Related]
37. Discovery of 5-substituted pyrrolo[2,3-d]pyrimidine antifolates as dual-acting inhibitors of glycinamide ribonucleotide formyltransferase and 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase in de novo purine nucleotide biosynthesis: implications of inhibiting 5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase to ampk activation and antitumor activity. Mitchell-Ryan S; Wang Y; Raghavan S; Ravindra MP; Hales E; Orr S; Cherian C; Hou Z; Matherly LH; Gangjee A J Med Chem; 2013 Dec; 56(24):10016-10032. PubMed ID: 24256410 [TBL] [Abstract][Full Text] [Related]
38. Synthesis, ADMET prediction and reverse screening study of 3,4,5-trimethoxy phenyl ring pendant sulfur-containing cyanopyrimidine derivatives as promising apoptosis inducing anticancer agents. Nainwal LM; Shaququzzaman M; Akhter M; Husain A; Parvez S; Khan F; Naematullah M; Alam MM Bioorg Chem; 2020 Nov; 104():104282. PubMed ID: 33010624 [TBL] [Abstract][Full Text] [Related]
39. Novel pyrazolo[3,4-d]pyrimidine derivatives inhibit human cancer cell proliferation and induce apoptosis by ROS generation. Gaonkar S; Savanur MA; Nadaf AA; Najare MS; Mantur S; Garbhagudi M; Mulla SI; Khazi IAM Arch Pharm (Weinheim); 2020 Apr; 353(4):e1900296. PubMed ID: 32073686 [TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of new cytotoxic azanaphthoquinone pyrrolo-annelated derivatives. Shanab K; Schirmer E; Knafl H; Wulz E; Holzer W; Spreitzer H; Schmidt P; Aicher B; Müller G; Günther E Bioorg Med Chem Lett; 2010 Jul; 20(13):3950-2. PubMed ID: 20537894 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]